VCAM-1 targeted alpha-particle therapy for early brain metastases.

ABSTRACT:

Background

Brain metastases (BM) develop frequently in patients with breast cancer. Despite the use of external beam radiotherapy (EBRT), the average overall survival is short (6 months from diagnosis). The therapeutic challenge is to deliver molecularly targeted therapy at an early stage when relatively few metastatic tumor cells have invaded the brain. Vascular cell adhesion molecule 1 (VCAM-1), overexpressed by nearby endothelial cells during the early stages of BM development, is a promising target. The aim of this study was to investigate the therapeutic value of targeted alpha-particle radiotherapy, combining lead-212 (212Pb) with an anti-VCAM-1 antibody (212Pb-αVCAM-1).

Methods

Human breast carcinoma cells that metastasize to the brain, MDA-231-Br-GFP, were injected i

SUBMITTER: Corroyer-Dulmont A 

PROVIDER: S-EPMC7162423 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature